Abstract:Abstract Ovarian cancer is the leading cause of death resulting from the cancer of female reproductive system. Matrix metalloproteinases (MMPs) are a family of zinc-dependent and structure related endopeptidases that have been implicated in the development and prognosis of cancers including ovarian cancer. In this case control study of 417 ovarian cancer cases and 417 healthy controls, we genotyped a comprehensive panel of 266 potential functional single nucleotide polymorphisms (SNPs) in 23 MMP genes and analyzed their associations with ovarian cancer risk, and overall survival and response to chemotherapy in ovarian cancer cases who received platinum-based chemotherapy with surgery. The analysis was further restricted to 339 Caucasian ovarian cancer cases and 349 Caucasian healthy controls to minimize potential confounding by population stratification. We observed 24 SNPs significantly associated with the risk of ovarian cancer, 4 of which remained significant after adjusting for multiple comparisons using q value at 10% level. The top 3 SNPs were from MMP20 and the most significant association was observed for SNP rs2292730 (OR = 2.03, 95% CI = 1.39 − 2.96, P = 0.0002, recessive model). We then analyzed the cumulative effect of the top four SNPs on ovarian cancer risk by counting the number of unfavorable genotypes in each individual and found a significant gene-dosage effect (P for trend < 0.0001). We applied classification and regression tree (CART) analysis to explore high order gene-gene interaction and identified 4 terminal nodes with differential risk of ovarian cancer (percentage of cases in terminal nodes ranging from 33% to 63%). In survival analysis, there were 42 SNPs significantly associated with overall survival, 34 of which remained significant after adjusting for multiple comparisons using q value at 10% level and 4 of which showed significant association with response to chemotherapy. The most significant association was observed for SNP rs2239008 from MMP1 (HR = 3.10, 95% CI = 1.54 − 6.24, P = 0.0016). We also studied the cumulative effect of the top SNPs on overall survival. Compared to low risk group of individuals with ≤ 11 unfavorable genotypes, patients with 12∼18 and ≥ 19 unfavorable genotypes had significantly increased risk of death (HR = 2.31, 95% CI = 1.51 − 3.51, and HR = 4.06, 95% CI = 2.45 − 6.73, respectively). The median survival times (MST) for patients having ≤ 11, 12∼18 and ≥ 19 unfavorable genotypes were 70.7, 40, and 25 months, respectively (log rank P < 0.0001). Survival tree analysis showed that patients can be differentiated into distinct risk groups based on their genetic profiles. There were 9 terminal nodes identified by the survival tree analysis with MSTs ranging from 18.2 to 151.7 months. In conclusion, our results suggest that genetic variants in MMP pathway genes may modulate the risk and clinical outcomes of ovarian cancer, both individually and jointly. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 2752.

Germline Gain‐Of‐Function Mmp11 Variant Results In An Aggressive Form Of Colorectal Cancer

A Single Nucleotide Polymorphism in the Matrix Metalloproteinase-2 Promoter is Associated with Colorectal Cancer.

Association of Matrix Metalloproteinase‐2 and ‐9 Promoter Polymorphisms with Colorectal Cancer in Chinese

The Impact of Matrix Metalloproteinase-11 Polymorphisms on Colorectal Cancer Progression and Clinicopathological Characteristics

Germline Variants of <i>CYBA</i> and <i>TRPM4</i> Predispose to Familial Colorectal Cancer

Matrix Metalloproteinase 11 Promotes Migration and Invasion of Colorectal Cancer by Elevating Slug Protein

A germline heterozygous nonsense mutation causes hereditary colorectal cancer

POLM Variant G312R Promotes Ovarian Tumorigenesis Through Genomic Instability and COL11A1-NF-κB Axis.

[The Correlation Between Polymorphisms of Matrix Metalloproteinase-2 and -9 Genes and Colorectal Cancer of Chinese Patients].

Nonsense suppression induces read‐through of a novel BMPR1A variant in a Chinese family with hereditary colorectal cancer

Matrix metalloproteinase 9 (MMP9) limits reactive oxygen species (ROS) accumulation and DNA damage in colitis-associated cancer

Prognostic Significance of Matrix Metalloproteinase 7 Immunohistochemical Expression in Colorectal Cancer: a Meta-Analysis.

Germline heterozygous exons 8-11 pathogenic BARD1 gene deletion reported for the first time in a family with suspicion of a hereditary colorectal cancer syndrome: more than an incidental finding?

Association of Clinicopathological Factors With MMP13 (rs2252070) Gene Polymorphism in Swedish Patients With Colorectal Cancer

A case of an unreported point mutation in promoter 1B of the adenomatous polyposis coli gene, which is responsible for gastric adenocarcinoma and proximal polyposis of the stomach

Extracellular Granzyme A Promotes Colorectal Cancer Development by Enhancing Gut Inflammation

RNF43 Pathogenic Germline Variant in a Family with Colorectal Cancer.

Germline NPAT inactivating variants as cause of hereditary colorectal cancer

Abstract 2752: Genetic Variants in MMPs Genes As Predisposition Factors for Ovarian Cancer Risk and Clinical Outcome

Genetic Variants in Matrix Metalloproteinase Genes As Disposition Factors for Ovarian Cancer Risk, Survival, and Clinical Outcome

Germline DNA Damage Repair Gene Alterations in Patients with Metachronous Breast and Colorectal Cancer